Current Research Studies
A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children from 1 to Less Than 18 Years of Age With PAH on Standard of Care
Sotatercept
What is the goal of the study?
This is a Phase 2, interventional, multicenter, open-label, single-group assignment study in participants ≥1 to <18 years of age with pah who group 1 based on documented historic diagnostic rhc. pah who group 1 consists of ipah heritable pah drug toxin-induced pah pah associated with ctd pah-chd with shunt closure more than 6 months before the screening period and pah associated with coincidental shunt. eligible participants will have pah classified as who fc i or symptomatic pah classified as who fc ii to iv.>
Who can participate in the study?
Please contact the study team listed below to learn more.